USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using …

Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis …

May 8, 2025 · On June 18, 2024, the FDA approved SKYRIZI for the treatment of adult patients with moderately to severely active ulcerative colitis. This milestone expands the drug’s …

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach …

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

SKYRIZI® is indicated for the treatment of moderately to severely active ulcerative colitis in adults. See Important Safety and Prescribing Information.

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This …

Jun 20, 2024 · The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works …

Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Drug-induced liver injury was reported in a patient with Crohn’s disease during induction dosing of SKYRIZI. …

Dec 13, 2025 · Skyrizi is administered as an intravenous infusion for the induction treatment of Crohn’s disease and ulcerative colitis, where Part B rules apply. This coverage scenario treats …